Trogocytosis is termed as the exchange of membrane-bound molecules, through which the immune response may be either enhanced or inhibited. This is a process in which T cells, B cells and natural killer cells bind to antigen-presenting cells and capture their cell surface molecules. It is suggested that trogocytosis-based T cell-T cell antigen presentation constitutes a natural part in immune response. T cells can acquire various molecules that function in antigen presentation via trogocytosis. These molecules are: CD80, CD86, OX40L, major histocompatibility complex (MHC-I) and MHC-II. Trogocytosis of peptide-antigen MHC (pMHC) complexes by T cells from their associated antigen presenting cells (APC) results in the activation or suppression of T cells. T cell-T cell interactions that occur when T cells present antigen to other T cells may be of critical importance for the activation of the T cell to which the antigen is presented. However, T cell-T cell interactions do not always result in the activation of immune cells. T cell which acquires pMHCs from its associated APC, can be lysed by surrounding T cells through peptide-specific cytotoxic T lymphocyte activity. Indeed, this event, in which a T cell is responsible for the lysis of another T cell, has been included in the literature with the term ‘Fratricide’. Trogocytosis, primarily defined in immune cells, may play a role in the prevention of hemolytic disease of the newborn, intercellular transmission of viruses and bacteria between cells, tumor microenvironment, formation of cancer metastases, or in the activation of the immune response against the tumor. By elucidating the mechanisms of trogocytosis and transphagocytosis, this study aims to highlight the potential for T cells to exhibit immune functions beyond their conventional roles and to shed light how these mechanisms may contribute significantly to the pathogenesis of various disease conditions.